Drug Discovery

Researchers develop new drug that could treat and limit Parkinson’s disease

Binghamton University researchers have developed a new drug that could possibly limit the progression of Parkinson’s disease and also provide better symptom relief.

Bristol-Myers Squibb to acquire IFM Therapeutics to expand cancer pipeline

Bristol-Myers Squibb has agreed to acquire Boston-based IFM Therapeutics for an upfront payment of $300m to strengthen its oncology pipeline.

VenatoRx secures $9.4m to develop new class of antibiotic fro multi-drug resistant bacteria

VenatoRx Pharmaceuticals, which focuses on discovery and development of novel therapies for highly drug resistant bacterial infections, has been awarded up to $9.4m from CARB-X (Combating Antibiotic-Resistant Bacteria Accelerator).

VenatoRx Pharmaceuticals raises $42m in new funding round

VenatoRx Pharmaceuticals has raised $42m in a Series B funding round led by Versant Ventures and joined by Abingworth and Foresite Capital.

Lilly and Nektar to jointly develop and commercialize autoimmune therapy

Eli Lilly and Company and Nektar Therapeutics have agreed to jointly develop NKTR-358, a novel immunological therapy discovered by the latter.

Study says machine learning algorithms can help predict schizophrenia

A new study has found that artificial intelligence (AI) and machine learning algorithms helped predict instances of schizophrenia with 74% accuracy.

UK awards more than £120m for global health research

The UK’s Department of Health has announced that 33 research units and groups will get over £120m funding for global health research.

Erytech, Queen’s University to advance eryminase program

Erytech Pharma and the Queen’s University in Canada have entered into a research collaboration to advance the preclinical development of the former’s eryminase program specifically for the treatment of arginase-1 deficiency.

Daiichi Sankyo, Max Planck and Lead Discovery enter into cancer research collaboration

Daiichi Sankyo, Max Planck Innovation and the Lead Discovery Center have inked an agreement offering Daiichi Sankyo with the option to receive the exclusive rights to a new lead compound for cancer treatment to be discovered and developed at the Lead Discovery Center.